0001375793 false --12-31 Q3 0001375793 2022-01-01 2022-09-30 0001375793 2022-11-15 0001375793 2022-09-30 0001375793 2021-12-31 0001375793 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001375793 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001375793 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001375793 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001375793 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001375793 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001375793 us-gaap:ProductMember 2022-07-01 2022-09-30 0001375793 us-gaap:ProductMember 2021-07-01 2021-09-30 0001375793 us-gaap:ProductMember 2022-01-01 2022-09-30 0001375793 us-gaap:ProductMember 2021-01-01 2021-09-30 0001375793 us-gaap:ServiceMember 2022-07-01 2022-09-30 0001375793 us-gaap:ServiceMember 2021-07-01 2021-09-30 0001375793 us-gaap:ServiceMember 2022-01-01 2022-09-30 0001375793 us-gaap:ServiceMember 2021-01-01 2021-09-30 0001375793 2022-07-01 2022-09-30 0001375793 2021-07-01 2021-09-30 0001375793 2021-01-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-06-30 0001375793 us-gaap:CommonStockMember 2022-06-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001375793 us-gaap:RetainedEarningsMember 2022-06-30 0001375793 2022-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-06-30 0001375793 us-gaap:CommonStockMember 2021-06-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001375793 us-gaap:RetainedEarningsMember 2021-06-30 0001375793 2021-06-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001375793 us-gaap:CommonStockMember 2021-12-31 0001375793 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001375793 us-gaap:RetainedEarningsMember 2021-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0001375793 us-gaap:CommonStockMember 2020-12-31 0001375793 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001375793 us-gaap:RetainedEarningsMember 2020-12-31 0001375793 2020-12-31 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-07-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-07-01 2022-09-30 0001375793 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001375793 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0001375793 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001375793 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-09-30 0001375793 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001375793 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001375793 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001375793 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-09-30 0001375793 us-gaap:CommonStockMember 2022-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001375793 us-gaap:RetainedEarningsMember 2022-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001375793 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001375793 us-gaap:CommonStockMember 2021-09-30 0001375793 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001375793 us-gaap:RetainedEarningsMember 2021-09-30 0001375793 2021-09-30 0001375793 MLRT:GlobalTrekXplorationIncAndLOCiMOBILEIncMember 2022-09-30 0001375793 MLRT:IPAndConsultingIncomeMember 2022-01-01 2022-09-30 0001375793 MLRT:IPAndConsultingIncomeMember 2021-01-01 2021-09-30 0001375793 MLRT:B2BMember 2022-01-01 2022-09-30 0001375793 MLRT:B2BMember 2021-01-01 2021-09-30 0001375793 MLRT:B2CMember 2022-01-01 2022-09-30 0001375793 MLRT:B2CMember 2021-01-01 2021-09-30 0001375793 MLRT:MilitaryMember 2022-01-01 2022-09-30 0001375793 MLRT:MilitaryMember 2021-01-01 2021-09-30 0001375793 MLRT:IPMember 2022-01-01 2022-09-30 0001375793 MLRT:IPMember 2021-01-01 2021-09-30 0001375793 MLRT:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerTwoMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerThreeMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerFourMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerFiveMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember MLRT:CustomerOneMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember MLRT:CustomerTwoMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember MLRT:CustomerThreeMember us-gaap:AccountsReceivableMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember MLRT:CustomerFourMember us-gaap:AccountsReceivableMember 2022-01-01 2022-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember MLRT:CustomerFiveMember us-gaap:AccountsReceivableMember 2022-01-01 2022-09-30 0001375793 MLRT:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerTwoMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerThreeMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember MLRT:CustomerOneMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember MLRT:CustomerTwoMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember MLRT:CustomerThreeMember us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0001375793 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember MLRT:CustomerMember 2021-01-01 2021-09-30 0001375793 MLRT:WarrantsMember 2022-01-01 2022-09-30 0001375793 MLRT:WarrantsMember 2021-01-01 2021-09-30 0001375793 MLRT:PreferredBSharesMember 2022-01-01 2022-09-30 0001375793 MLRT:PreferredBSharesMember 2021-01-01 2021-09-30 0001375793 MLRT:PreferredCSharesMember 2022-01-01 2022-09-30 0001375793 MLRT:PreferredCSharesMember 2021-01-01 2021-09-30 0001375793 MLRT:ConversionSharesUponConversionOfNotesMember 2022-01-01 2022-09-30 0001375793 MLRT:ConversionSharesUponConversionOfNotesMember 2021-01-01 2021-09-30 0001375793 MLRT:InventergyGlobalIncMember 2020-12-31 0001375793 MLRT:InventergyGlobalIncMember 2022-06-30 0001375793 MLRT:InventergyGlobalIncMember 2022-09-30 0001375793 MLRT:InpixonMember 2019-06-01 2019-06-30 0001375793 MLRT:InpixonMember 2019-01-01 2019-12-31 0001375793 2020-01-01 2020-03-31 0001375793 MLRT:InpixonMember 2020-01-01 2020-03-31 0001375793 MLRT:InpixonMember 2021-01-01 2021-12-31 0001375793 MLRT:InpixonMember 2022-01-01 2022-09-30 0001375793 MLRT:InpixonMember 2022-06-30 0001375793 MLRT:SoftwareMember 2022-09-30 0001375793 MLRT:SoftwareMember 2021-12-31 0001375793 MLRT:WebsiteDevelopmentMember 2022-09-30 0001375793 MLRT:WebsiteDevelopmentMember 2021-12-31 0001375793 us-gaap:SoftwareDevelopmentMember 2022-09-30 0001375793 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001375793 us-gaap:EquipmentMember 2022-09-30 0001375793 us-gaap:EquipmentMember 2021-12-31 0001375793 MLRT:UnsecuredTermLoanAgreementMember MLRT:ThirdPartyMember 2022-09-30 0001375793 MLRT:UnsecuredTermLoanAgreementMember MLRT:ThirdPartyMember 2022-01-01 2022-09-30 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2019-09-30 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2019-09-27 2019-09-30 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2021-12-31 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2021-01-01 2021-12-31 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2022-09-30 0001375793 MLRT:AssetPurchaseAgreementMember MLRT:ThirdPartyMember 2022-01-01 2022-09-30 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember 2018-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember MLRT:ThreeBorrowingMember 2018-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember MLRT:TwoBorrowingMember 2019-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember 2019-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember 2020-01-01 2020-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember 2020-12-31 0001375793 MLRT:LineofCreditAgreementMember MLRT:AccreditedInvestorMember 2021-01-01 2021-12-31 0001375793 MLRT:LineofCreditAgreementMember 2022-09-30 0001375793 us-gaap:LineOfCreditMember us-gaap:InvestorMember 2022-01-01 2022-09-30 0001375793 us-gaap:InvestorMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001375793 MLRT:UnionBankMember 2022-01-01 2022-09-30 0001375793 MLRT:UnionBankMember 2021-12-31 0001375793 MLRT:UnionBankMember 2022-09-30 0001375793 MLRT:ConvertibleNotesWithFixedConversionMember 2022-06-30 0001375793 MLRT:ConvertibleNotesWithFixedConversionMember 2021-12-31 0001375793 us-gaap:ConvertibleNotesPayableMember MLRT:ThirdPartyMember 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember MLRT:ThirdPartyMember 2022-01-01 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember srt:MinimumMember 2022-01-01 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember srt:MaximumMember 2022-01-01 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember 2020-12-31 0001375793 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001375793 MLRT:EmployeeNotesMember MLRT:ThirdPartyMember 2021-01-01 2021-12-31 0001375793 MLRT:ConvertibleEmployeePromissoryNotesPayableMember 2021-01-01 2021-12-31 0001375793 us-gaap:ConvertibleNotesPayableMember 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember MLRT:ThirdPartyMember 2022-01-01 2022-09-30 0001375793 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001375793 MLRT:PaycheckProtectionProgramMember 2020-04-30 0001375793 MLRT:PaycheckProtectionProgramMember 2021-12-31 0001375793 MLRT:PaycheckProtectionProgramLoanMember 2022-01-01 2022-09-30 0001375793 MLRT:SBALoanAgreementMember MLRT:EIDLLoanMember 2020-06-10 0001375793 MLRT:SBALoanAgreementMember MLRT:EIDLLoanMember 2020-06-09 2020-06-10 0001375793 MLRT:EIDLLoanMember 2022-01-01 2022-09-30 0001375793 MLRT:EIDLLoanMember 2022-09-30 0001375793 MLRT:RelatedPartiesMember 2021-12-31 0001375793 MLRT:RelatedPartiesMember 2021-01-01 2021-12-31 0001375793 MLRT:ConvertiblePromissoryNotesMember 2021-12-31 0001375793 MLRT:ConvertiblePromissoryNotesMember 2020-12-31 0001375793 MLRT:ConvertiblePromissoryNotesMember 2020-01-01 2020-12-31 0001375793 MLRT:ConvertiblePromissoryNotesMember 2021-07-01 0001375793 MLRT:ConvertiblePromissoryNotesMember 2022-09-30 0001375793 MLRT:ThirdPartyMember 2022-09-30 0001375793 MLRT:BoardOfDirectorsMember 2022-09-30 0001375793 us-gaap:PreferredStockMember 2022-09-20 2022-09-20 0001375793 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001375793 us-gaap:SeriesAPreferredStockMember MLRT:OfficersAndBoardMembersMember 2018-01-01 2018-12-31 0001375793 MLRT:BoardOfDirectorsMember us-gaap:SeriesAPreferredStockMember 2020-01-31 2020-01-31 0001375793 us-gaap:SeriesAPreferredStockMember MLRT:BoardOfDirectorsMember 2020-01-31 0001375793 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001375793 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-12-31 0001375793 us-gaap:SeriesBPreferredStockMember MLRT:AccreditedInvestorMember 2020-01-01 2020-12-31 0001375793 us-gaap:SeriesBPreferredStockMember MLRT:AccreditedInvestorMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001375793 us-gaap:SeriesBPreferredStockMember MLRT:AccreditedInvestorMember 2020-12-31 0001375793 us-gaap:SeriesBPreferredStockMember MLRT:TwoAccreditedInvestorsMember 2021-01-01 2021-12-31 0001375793 us-gaap:SeriesBPreferredStockMember MLRT:TwoAccreditedInvestorsMember 2021-12-31 0001375793 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001375793 us-gaap:SeriesCPreferredStockMember MLRT:TwoAccreditedInvestorsMember 2020-01-01 2020-12-31 0001375793 us-gaap:SeriesCPreferredStockMember MLRT:TwoAccreditedInvestorsMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001375793 MLRT:AccerditedInverstorMember 2021-01-01 2021-12-31 0001375793 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001375793 2021-01-01 2021-12-31 0001375793 us-gaap:SeriesCPreferredStockMember MLRT:TwoAccreditedInvestorsMember 2021-01-01 2021-12-31 0001375793 us-gaap:SeriesCPreferredStockMember MLRT:TwoAccreditedInvestorsMember 2021-12-31 0001375793 us-gaap:CommonStockMember 2022-09-20 2022-09-20 0001375793 MLRT:VariousFirmsMember 2022-01-01 2022-09-30 0001375793 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001375793 MLRT:RegulationAOfferingMember 2021-10-14 2021-10-15 0001375793 MLRT:RegulationAOfferingMember 2021-10-15 0001375793 MLRT:RegulationAOfferingMember 2022-01-01 2022-09-30 0001375793 MLRT:CommonStockWarrantsMember 2022-09-30 0001375793 MLRT:CommonStockWarrantsMember 2022-01-01 2022-09-30 0001375793 us-gaap:WarrantMember 2022-09-30 0001375793 MLRT:TwoThousandEightEquityCompensationPlanMember 2022-09-30 0001375793 srt:MinimumMember 2021-12-31 0001375793 srt:MaximumMember 2021-12-31 0001375793 srt:MinimumMember 2022-09-30 0001375793 srt:MaximumMember 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeOneMember 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeOneMember 2022-01-01 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeTwoMember 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeTwoMember 2022-01-01 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeThreeMember 2022-09-30 0001375793 us-gaap:WarrantMember MLRT:ExercisePriceRangeThreeMember 2022-01-01 2022-09-30 0001375793 MLRT:BoardOfDirectorsMember srt:MinimumMember 2022-09-30 0001375793 MLRT:BoardOfDirectorsMember srt:MaximumMember 2022-09-30 0001375793 us-gaap:DeferredBonusMember 2022-01-01 2022-09-30 0001375793 MLRT:ConsultantForServicesMember us-gaap:SubsequentEventMember 2022-10-27 2022-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MLRT:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended September 30, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission file number 000-53046

 

METALERT INC.

(Exact name of registrant as specified in its charter)

 

Nevada   98-0493446
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

117 W. 9th Street, Suite 1214, Los Angeles, CA, 90015
(Address of principal executive offices) (Zip Code)

 

(213) 489-3019
(Registrant’s telephone number, including area code)

 

GTX Corp

 

(Former Name or former Address, if Changed Since Last Report) 

 

Title of each class registered:   Trading Symbol(s)   Name of each exchange on which registered:
None   GTXO   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   Accelerated filer
Non-accelerated filer ☐ (Do not check if a smaller reporting company)   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 15,568,504 common shares issued and outstanding as of November 15, 2022.

 

 

 

 
 

 

METALERT INC. AND SUBSIDIARIES

For the quarter ended September 30, 2022

FORM 10-Q

 

    PAGE NO.
PART I. FINANCIAL INFORMATION  
     
Item 1. Condensed Financial Statements 3
     
  Condensed Consolidated Balance Sheets at September 30, 2022 (unaudited) and December 31, 2021 (audited) 3
  Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 (unaudited) 4
  Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2022 and 2021 (unaudited) 5
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited) 7
  Notes to Condensed Consolidated Financial Statements (unaudited) 8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 22
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 29
     
Item 4. Controls and Procedures 29
     
PART II. OTHER INFORMATION 29
     
Item 1. Legal Proceedings 29
     
Item 1A. Risk Factors 29
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
     
Item 3. Defaults Upon Senior Securities 30
     
Item 4. Mine Safety Disclosures 30
     
Item 5. Other Information 31
     
Item 6. Exhibits 31
     
  Signatures 32

 

2
 

 

PART I

 

ITEM 1. FINANCIAL STATEMENTS

 

METALERT INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2022 AND DECEMBER 31, 2021

 

  

September 30,

2022

  

December 31,

2021

 
    (Unaudited)      
ASSETS          
Current assets:          
Cash and cash equivalents  $23,998   $138,342 
Accounts receivable, net   23,328    13,735 
Inventory   90,997    98,258 
Investment in marketable securities   1,096    2,465 
Other current assets   17,827    55,016 
Total current assets   157,246    307,816 
           
Property and equipment, net   67,456    92,461 
Intangible assets, net   3,308    - 
           
Total assets  $228,010   $400,277 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $127,220   $182,610 
Accrued expenses   334,106    327,293 
Accrued expenses, related parties   579,245    839,810 
Deferred revenues   15,975    37,350 
Short-term debt – line of credit   17,000    21,715 
Short-term debt - Care loans   6,625    74,953 
Convertible promissory notes, past due   843,000    758,000 
Convertible notes, related parties, net of discount   1,104,585    976,545 
Notes payable   150,875    40,640 
Total current liabilities   3,178,631    3,136,981 
           
Long-term debt - CARE loan, net of current   143,375    142,917 
           
Total liabilities   3,322,006    3,279,898 
           
Commitments and contingencies   -    - 
           
Stockholders’ deficit:          
Preferred stock series A, $0.001 par value; 1,000,000 shares authorized; 13,846 shares issued and outstanding at September 30, 2022 and 15,385 December 31, 2021, respectively   14    15 
Preferred stock series B, $0.001 par value; 10,000 shares authorized, 3 and 3 issued and outstanding at September 30, 2022 and December 31, 2021, respectively   -    - 
Preferred stock series C, $0.001 par value; 1,000 shares authorized, 11 and 11 issued and outstanding at September 30, 2022 and December 31, 2021, respectively   -    - 
Common stock, $0.0001 par value; 2,071,000,000 shares authorized; 15,565,927 and 3,453,885 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively   1,556    345 
Additional paid-in capital   23,680,890    23,173,403 
Accumulated deficit   (26,776,456)   (26,053,384)
Total stockholders’ deficit   (3,093,996)   (2,879,621)
Total liabilities and stockholders’ deficit  $228,010   $400,277 

 

See accompanying notes to condensed consolidated financial statements.

 

3
 

 

METALERT INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

(Unaudited)

 

   2022   2021   2022   2021 
         
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2022   2021   2022   2021 
Product sales  $36,352   $112,974   $200,277   $397,963 
Service income   31,302    38,580    100,293    143,715 
Total revenues   67,653    151,554    300,570    541,678 
                     
Cost of products sold   23,333    58,001    147,267    200,055 
Cost of other revenue   3,016    10,129    15,906    63,556 
Total cost of goods sold   26,349    68,130    163,173    263,611 
                     
Gross margin   41,305    83,424    137,397    278,067 
                     
Operating expenses:                    
Wages and benefits   127,829    138,137    382,916    358,099 
Professional fees   81,893    65,902    257,232    263,863 
Sales and marketing expenses   3,494    5,083    19,092    74,821 
General and administrative   68,269    70,001    156,670    159,702 
                     
Total operating expenses   281,485    279,123    815,911    883,484 
                     
Income/(loss) from operations   (240,180)   (195,699)   (678,514)   (605,418)
                     
Other income/(expenses):                    
Gain/(loss) on settlement of debt   -    -    -    (66,036)
Gain/(loss) on marketable securities   (94)   (1,101)   (1,369)   (419)
Amortization of debt discount   (16,526)   -    (29,089)   - 
Grant from Care loans   -    -    67,870    - 
EDD Recovery due to COVID             34,191    

 
Interest imputed on related party notes   -    -    -    (30,705)
Interest expense and financing costs   (45,663)   (15,331)   (116,161)   (55,469)
                     
Total other income/(expenses)   (62,284)   (16,432)   (44,558)   (152,628)
                     
Net income/(loss)   (302,463)   (212,131)   (723,072)   (758,046)
                     
Deemed dividend to series-B preferred stockholders   -    -    -    - 
Deemed dividend to series-C preferred stockholders   -    -    -    (675,000)
                     
Net income/(loss) attributable to common shareholders  $(302,463)  $(212,131)  $(723,072)  $(1,433,046)
                     
Weighted average number of common shares outstanding - basic and diluted   5,066,220    3,306,193    4,161,828    2,974,597 
                     
Net income/(loss) per common share - basic and diluted  $(0.06)  $(0.06)  $(0.17)  $(0.26)

 

See accompanying notes to condensed consolidated financial statements.

 

4
 

 

METALERT INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022 AND SEPTEMBER 30, 2021

(Unaudited)

 

For the Three Months Ended September 30, 2022 (Unaudited)

 

   Issued   Amount   Issued   Amount   Issued   Amount   Issued   Amount   Capital   Deficit   (Deficit) 
   Series A
Preferred
   Series B
Preferred
   Series C
Preferred
   Common Shares   Additional         
   Shares       Shares       Shares       Shares       Paid-In   Accumulated   Equity 
   Issued   Amount   Issued   Amount   Issued   Amount   Issued   Amount   Capital   Deficit   (Deficit) 
Balance June 30, 2022   15,385   $15    3   $-    11   $-    3,801,655   $380   $23,419,068   $(26,473,993)  $(3,052,303)
Issuance of common stock for services   -    -    -    -    -    -    342,693    34    57,075    -    57,109 
Issuance of common stock for the conversion of notes                                 11,406,200    1,141    112,921         114,062 
Issuance of common stock for financings   -    -    -    -    -    -    15,385    2    30,491    -    30,492 
Issuance of common stock for the conversion of warrants   -    -    -    -    -    -    -    -    

985

    -    

985

 
Preferred A to treasury   (1,539)   (1)                                 1           
Debt discount   -    -    -    -    -    -    -    -    60,349    -    60,349 
Net income (loss)   -    -    -    -    -    -    -    -    -    (302,463)   (302,463)
Balance September 30, 2022   13,846   $14    3   $-    11   $-    15,565,933   $1,556   $23,680,890   $(26,776,456)  $(3,093,996)

 

For the Three Months Ended September 30, 2021 (Unaudited)

 

   Series A Preferred   Series B Preferred   Series C Preferred   Common Shares   Additional         
   Shares       Shares       Shares       Shares       Paid-In   Accumulated   Equity 
   Issued   Amount   Issued   Amount   Issued   Amount   Issued   Amount   Capital   Deficit   (Deficit) 
Balance June 30, 2021   1,000,000   $100    204   $1    675   $-    214,702,481   $21,470   $23,016,911   $(25,398,841)  $(2,360,358)
Issuance of common stock for services   -    -    -    -    -    -    200,000    20    2,940    -    2,960 
Net income (loss)   -    -    -    -    -    -    -    -    -    (212,131)   (212,131)
Balance September 30, 2021   1,000,000   $100    204   $1    675   $1    214,902,481   $21,490   $23,019,851   $(25,610,972)  $(2,569,529)

 

5
 

 

METALERT INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND SEPTEMBER 30, 2021

(Unaudited)

 

For the Nine Months Ended September 30, 2022 (Unaudited)

 

   Series A
Preferred
   Series B
Preferred
   Series C
Preferred
   Common Shares   Additional         
   Shares       Shares       Shares       Shares       Paid-In   Accumulated   Equity 
   Issued   Amount   Issued   Amount   Issued   Amount   Issued   Amount   Capital   Deficit   (Deficit) 
Balance December 31, 2021   15,385   $15    3   $-    11   $-    3,453,885   $345   $23,175,727   $(26,053,384)  $(2,879,621)
Issuance of common stock for services   -    -    -    -    -    -    459,692    46    129,240    -    129,286 
Issuance of common stock for financings   -    -    -    -    -    -    92,309    9    179,991    -    180,000 
Issuance of common stock for the conversion of notes   -    -    -    -    -    -    11,406,200    1,141    112,921    -    114,062 
Issuance of common stock for the conversion of warrants   -    -    -    -    -    -    153,847    15    24,985    -    25,000 
Return of preferred stock to treasury   

(1,539

)   

(1

)   -   -    -    -    -    -    1    -    - 
Debt discount                                           60,349         60,349 
Net income (loss)   -    -    -    -    -    -    -    -    -    (723,072)   (723,072)
Balance September 30, 2022   13,846   $14    3   $-    11   $--    15,565,933   $1,556   $23,680,890   $(26,776,456)  $(3,093,996)

 

For the Six Months Ended September 30, 2021 (Unaudited)

 

   Series A Preferred   Series B Preferred   Series C Preferred   Common Shares   Additional         
   Shares       Shares       Shares       Shares       Paid-In   Accumulated   Equity 
   Issued   Amount   Issued   Amount   Issued   Amount   Issued   Amount   Capital   Deficit   (Deficit) 
Balance December 31, 2020   1,000,000   $100    250   $1    150   $-    138,032,482   $13,803   $21,059,925   $(24,177,926)  $(3,104,097)
Issuance of common stock for services   -    -    -    -    -    -    8,850,000    885    240,822    -    241,110 
Loss on stock compensation   -    -    -    -    -    -    -    -    14,075    -    14,075 
Issuance of common stock for conversion of debt   -    -    -    -    -    -    16,661,660    1,666    192,707    -    194,373 
Issuance of preferred stock for financings   -    -    -    -    675    1    -    -    674,999    -    675,000 
Issuance of common stock for financings   -    -    -    -    -    -    250,000    25    3,250    -    3,275 
Issuance of common stock for the conversion of warrants   -    -    -    -    -    -    22,708,335    2,271    (2,271)   -    - 
Issuance of common stock for the conversion of preferred shares   -    -    (46)   -    (150)   -    28,400,004    2,840    (2,840)   -    - 
Loss on shares issued for conversion of debt                                           131,736         131,736 
Deemed dividend on fair value of warrants & conversion feature   -    -    -    -    -    -    -    -    675,000    (675,000)   - 
Imputed interest – related parties   -    -    -    -    -    -    -    -    30,705    -    30,705 
Inpixon loan reduction correction   -    -    -    -    -    -    -    -    2,340    -    2,340 
Net income (loss)   -    -    -    -    -    -    -    -    -    (758,046)   (758,046)
Balance September 30, 2021   1,000,000   $100    204   $1    675   $1    214,902,481   $21,490   $23,019,851   $(25,610,972)  $(2,569,529)

 

See accompanying notes to condensed consolidated financial statements.

 

6
 

 

METALERT INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

(Unaudited)

 

   2022   2021 
   Nine Months Ended September 30, 
   2022   2021 
Cash flows from operating activities          
Net income / (loss)  $(723,072)  $(758,046)
Adjustments to reconcile net income / (loss) to net cash used in operating activities:          
Depreciation and amortization   25,005    7,103 
Bad debt expense   -    34,675 
Change in fair value of marketable securities   1,369    419 
Stock based compensation   129,286    255,185 
Grant from CARE loans   (67,870)   - 
Amortization of debt discount   29,089    - 
Interest and financing cost on LT convertible debt   116,641    - 
Issuance of common stock for financings   -    43,413 
Loss on the settlement of debt and accrued interest   -    66,036 
Fair value of warrants issued for services   -    2,340 
Imputed interest on related party notes   -    30,705 
Changes in operating assets and liabilities:          
Accounts receivable   (9,592)   (41,963)
Inventory   7,261    4,710 
Other current and non-current assets   37,189    (91,864)
Accounts payable and accrued expenses   (33,563)   (30,990)
Accrued expenses - related parties   82,698    106,621 
Deferred revenues   (21,275)   (6,370)
           
Net cash used in operating activities   (426,835)   (378,026)
           
Cash flows from investing activities          
Intangible asset purchases   (3,308)   - 
PP&E purchases   -    (64,500)
Proceeds from the sale of marketable securities   -    1,258 
           
Net cash used in investing activities   (3,308)   (63,242)
           
Cash flows from financing activities          
Proceeds from line of credit   69,180    - 
Proceeds from issuance of preferred stock   -    675,000 
Proceeds from the exercise of warrants   25,000    - 
Proceeds from Reg A   180,000    - 
Borrowings on debt   145,000    - 
Payments on notes   -    - 
Payments on line of credit   (59,180)   - 
Payments on debt   (44,201)   (17,123)
           
Net cash provided by financing activities   315,799    657,877 
           
Net change in cash and cash equivalents   (114,345)   216,609 
           
Cash and cash equivalents, beginning of period   138,342    76,912 
           
Cash and cash equivalents, end of period  $23,998   $293,521 
           
Supplemental disclosure of cash flow information:          
Income taxes paid  $-   $- 
Interest paid  $-   $623 
           
Supplemental disclosure of noncash investing and financing activities:          
Issuance of common stock for conversion of debt and interest  $114,062   $194,373 
Deemed dividend  $-   $675,000 
Conversion of preferred stock to common stock  $-   $2,841 

 

See accompanying notes to condensed consolidated financial statements.

 

7
 

 

METALERT INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

(Unaudited)

 

1. ORGANIZATION AND BASIS OF PRESENTATION

 

During the periods covered by these financial statements, MetAlert Inc. (formerly known as GTX Corp) and its subsidiaries (the “Company”, “GTX”, “we”, “us”, and “our”) were engaged in business operations that design, manufacture and sell various interrelated and complementary products and services in the wearable technology and Personal Location Services marketplace. MetAlert, Inc. owns 100% of the issued and outstanding capital stock of its two subsidiaries - Global Trek Xploration, Inc. and LOCiMOBILE, Inc.

 

Global Trek Xploration, Inc. focuses on the design, manufacturing and sales distribution of its hardware, software, and connectivity, Global Positioning System (“GPS”) and Bluetooth Low Energy (“BLE”) monitoring and tracking platform, which provides real-time tracking and monitoring of people and high valued assets. Utilizing a miniature quad-band GPRS transceiver, antenna, circuitry, battery and inductive charging pad our solutions can be customized and integrated into numerous products whose location and movement can be monitored in real time over the Internet through our 24x7 tracking portal or on a web enabled cellular telephone. Our core products and services are supported by an intellectual property (“IP”) portfolio of patents, patents pending, registered trademarks, copyrights, URLs and a library of software source code, all of which is also managed by Global Trek.

 

LOCiMOBILE, Inc., is the Companies digital platform which has been at the forefront of Smartphone application (“App”) development since 2008. With a suite of mobile applications that turn the iPhone, iPad, Android and other GPS enabled handsets into a tracking device which can be tracked from handset to handset or through our tracking portal or on any connected device with internet access. LOCiMOBILE has launched over 20 Apps across multi mobile device operating systems and continues to launch consumer and enterprise apps.

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements of MetAlert, Inc. have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and applicable regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of financial position and results of operations have been included. Our operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2021, which are included in our Annual Report on Form 10-K.

 

The accompanying consolidated financial statements reflect the accounts of MetAlert, Inc. and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated.

 

On September 20, 2022, as previously disclosed, the Company effected a 1-for-65 reverse stock split of its common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these consolidated financial statements and notes to consolidated financial statements have been restated to reflect the reverse stock split on a retroactive basis.

 

Going Concern

 

The consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has a stockholders’ deficit of $3,093,996 and negative working capital of $3,021,385 as of September 30, 2022 and used cash in operations during the period then ended. The Company anticipates further losses in the development of its business. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its business plan until such time as revenues and related cash flows are sufficient to fund our operations.

 

8
 

 

The Company’s independent registered public accounting firm has also included explanatory language in their opinion accompanying the Company’s audited financial statements for the year ended December 31, 2021. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company’s ability to raise additional capital through the future issuances of debt or equity is unknown. The ability to obtain additional financing, the successful development of the Company’s contemplated plan of operations, or its ability to achieve profitable operations are necessary for the Company to continue operations, and there is no assurance that these can be achieved. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

2. SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.

 

The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time.

 

All of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company does not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

We derive our revenues primarily from hardware sales, subscription services fees, IP licensing and professional services fees. Hardware includes our SmartSole, Military and other Stand-Alone Devices. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and subscription or license fees for our platform. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training and managed services related to our solutions. IP licensing is related to our agreement with Inventergy whereby we have partnered in order to monetize our IP portfolio.

 

9
 

 

Product sales

 

At the inception of each contract, we assess the goods and services promised in our contracts and identify each distinct performance obligation. The Company recognizes revenue upon the transfer of control of promised products or services to the customer in an amount that depicts the consideration the Company expects to be entitled to for the related products or services. For the large majority of the Company’s sales, transfer of control occurs once product has shipped and title and risk of loss have transferred to the customer.

 

Services Income

 

The Company’s software solutions are available for use as hosted application arrangements under subscription fee agreements without licensing perpetual rights to the software. Subscription fees from these applications are recognized over time on a ratable basis over the customer agreement term beginning on the date the Company’s solution is made available to the customer. Our subscription contracts are generally one to three months in length. Amounts that have been invoiced are recorded in accounts receivable and deferred revenues or revenues, depending on whether the revenue recognition criteria have been met.

 

The majority of our professional services arrangements are recognized on a time and materials basis. Professional services revenues recognized on a time and materials basis are measured monthly based on time incurred and contractually agreed upon rates. Certain professional services revenues are based on fixed fee arrangements and revenues are recognized based on the proportional performance method. In some cases, the terms of our time and materials and fixed fee arrangements may require that we defer the recognition of revenue until contractual conditions are met. Data services and training revenues are generally recognized as the services are performed.

 

IP Licensing Revenue

 

Licensing revenue recorded by the Company relates exclusively to the Company’s License and Partnership agreement with Inventergy which provides for ongoing royalties based on monetization of IP licenses. The Company recognizes revenue for royalties under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the following: 1) sale or usage of the products or 2) satisfaction of the performance obligations. The Company has satisfied its performance obligations and therefore recognizes licensing revenue when the sales to which the license(s) relate are completed. During the periods ended June 30, 2022 and June 30, 2021, the Company did not recognize any licensing revenue.

 

Disaggregation of Net Sales

 

The following table shows the Company’s disaggregated net sales by product type:

 

  

September 30,

2022

  

September 30,

2021

 
Product sales  $200,277   $397,963 
Service income   100,293    143,715 
IP and consulting income   -    - 
Total  $300,570   $541,678 

 

The following table shows the Company’s disaggregated net sales by customer type:

 

    September 30, 2022     September 30, 2021  
B2B   $ 195,386     $ 150,180  
B2C     105,184       381,321  
Military     -       10,117  
IP     -       -  
Total   $ 300,570     $ 541,678  

 

10
 

 

Allowance for Doubtful Accounts

 

We extend credit based on our evaluation of the customer’s financial condition. We carry our accounts receivable at net realizable value. We monitor our exposure to losses on receivables and maintain allowances for potential losses or adjustments. We determine these allowances by (1) evaluating the aging of our receivables; and (2) reviewing high-risk customers financial condition. Past due receivable balances are written off when our internal collection efforts have been unsuccessful in collecting the amount due. Our allowance for doubtful accounts was $38,920 as of September 30, 2022 and $40,351 as of December 31, 2021. The allowance fully reserves our accounts receivable balances over 90 days.

 

Shipping and Handling Costs

 

Shipping and handling costs are included in cost of goods sold in the accompanying consolidated statements of operations.

 

Product Warranty

 

The Company’s warranty policy provides repair or replacement of products (excluding GPS Shoe devices) returned for defects within ninety days of purchase. The Company’s warranties are of an assurance-type and come standard with all Company products to cover repair or replacement should product not perform as expected. Provisions for estimated expenses related to product warranties are made at the time products are sold. These estimates are established using historical information about the nature, frequency and average cost of warranty claim settlements as well as product manufacturing and recovery from suppliers. Management actively studies trends of warranty claims and takes action to improve product quality and minimize warranty costs. The Company estimates the actual historical warranty claims coupled with an analysis of unfulfilled claims to record a liability for specific warranty purposes. As of September 30, 2022 and 2021, products returned for repair or replacement have been immaterial. Accordingly, a warranty liability has not been deemed necessary.

 

Use of Estimates

 

The preparation of the accompanying unaudited financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, estimates related to revenue recognition, allowance for doubtful accounts, inventory valuation, tangible and intangible long-term asset valuation, warranty and other obligations and commitments. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.

 

Fair Value Estimates

 

Pursuant to the Accounting Standards Codification (“ASC”) No. 820, “Disclosures About Fair Value of Financial Instruments”, the Company records its financial assets and liabilities at fair value. ASC No. 820 provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. ASC No. 820 establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

  Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
     
  Level 2 - Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the asset/liability’s anticipated life.
     
  Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

 

11
 

 

The carrying values for cash and cash equivalents, accounts receivable, investment in marketable securities, other current assets, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The carrying values of notes payable and other financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

 

Concentrations

 

We currently rely on one manufacturer to supply us with our GPS SmartSole and one manufacturer to supply us with the GPS device included in the GPS SmartSole. The loss of either of these manufacturers could severely impede our ability to manufacture the GPS SmartSole.

 

As of September 30, 2022, the Company had five customers representing approximately 28%, 23%, 16%, 6% and 6% of sales, respectively (34% in receivables represents sales made through our online stores and consists of approximately 2,000 different customers), and five customers representing approximately 25%, 18%, 18, 12%% and 8% of total accounts receivable, respectively (excluding related party payables).

 

For the nine months ended September 30, 2021, the Company had three customers representing approximately 76%, 8% and 4% of sales, respectively, and three customers representing approximately 31%, 13% and 8% of total accounts receivable, respectively (of the 76% of sales, this represents all sales made through our online store and consists of approximately 2,000+ different customers).

 

Stock-based Compensation

 

The Company accounts for share-based awards to employees and nonemployees directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation., and under the recently issued guidance following FASB’s pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur.

 

Marketable Securities

 

The Company’s securities investments that are acquired and held principally for the purpose of selling them in the near term are classified as trading securities. Trading securities are recorded at fair value based on quoted market price (level 1) on the balance sheet in current assets, with the change in fair value during the period included in earnings. As of September 30, 2022 and December 31, 2021 the fair value of our investment in marketable securities was $1,096 and $2,465.

 

Derivative Liabilities

 

Our derivative instrument liabilities are re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income, in the period in which the changes occur. For bifurcated conversion options that are accounted for as derivative instrument liabilities, we determine the fair value of these instruments using the Black-Scholes option pricing model. This model requires assumptions related to the remaining term of the instrument and risk-free rates of return, our current Common Stock price and expected dividend yield, and the expected volatility of our Common Stock price over the life of the option.

 

At September 30, 2022 and December 31, 2021, the balance of the derivative liabilities was $0. It was determined at December 31, 2020 that the Preferred A shareholders having the majority vote, can agree to increase the number of authorized shares, if needed, to settle any convertible debt, and thus the liability is $0.

 

12
 

 

Net Loss Per Common Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

 

   2022   2021 
   September 30, 
   2022   2021 
Warrants   603,846    757,703 
Preferred B shares   24,616    266,667 
Preferred C shares   10,264    2,750,000 
Conversion shares upon conversion of notes   174,250,425    117,414,615 
Total   174,889,151    121,188,985 

 

Segments

 

The Company operates in one segment for the manufacture and distribution of its products. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures.

 

Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

13
 

 

3. INVESTMENT IN MARKETABLE SECURITIES

 

The Company’s investments in marketable securities is comprised of shares of stock of two (2) entities with ownership percentages of less than 5%. The Company accounted for these investments pursuant to ASU 320, Investments – Debt and Equity Securities. As such, these investments were recorded at their market value as of December 31, 2019, with the change in fair value being reflected in the statement of operations. These investments consisted of the following:

 

As of December 31, 2020, the Company owned 42,500 shares of Inventergy Global, Inc. common stock with a fair value of $1,275. The Company was able to obtain observable evidence that the investment had a market value of $0.02 per share, or an aggregate value of $850 as of the period ended September 30, 2022. As such, the Company recorded no change in market value during the nine months ended June 30, 2022, in its statement of operations.

 

In June 2019, the Company acquired 22,222 shares of Inpixon’s restricted common stock (after giving effect to a 1:45 stock split) valued at $634,000. As of December 31, 2019, after the sale of 10,889 Inpixon shares, the Company owned 11,333 Inpixon shares with a fair value of $58,374. During the period ended March 31, 2020, the Company sold 8,500 of its Inpixon shares for total proceeds of $146,201 and recognized a gain from the sale of these shares of $102,420.

 

During the period ended December 31, 2021, the Company sold 834 of its Inpixon shares for total net proceeds of $1,258. The Company was able to obtain observable evidence that the remaining 2,000 shares had a market value of $2,040 as of December 31, 2021, as such, the Company recorded a loss from the decrease in the fair value of the shares of $851, resulting in a net loss from their investment in Inpixon shares during the current period ended December 31, 2021.

 

During the nine months ended September 30, 2022, the Company sold 834 shares of its Inpixon shares for total proceeds of $1,334 and recognized a gain from the sale of these shares of $1,258.

 

The Company was able to obtain observable evidence that the remaining 2,000 shares (now adjusted for a 75-1 split to 27 shares) had a market value of $9.225 per share, or an aggregate value of $246 as of September 30, 2022, as such, the Company recorded a change in the fair value of the shares, resulting in a net loss from the investment in Inpixon shares of $1,794 during the current period ended September 30, 2022.

 

4. INVENTORY

 

Inventories consist of the following:

 

   September 30, 2022   December 31, 2021 
Raw materials  $32,162   $71,936 
Finished goods   58,835    25,322 
Total Inventories  $90,997   $98,258 

 

5. PROPERTY AND EQUIPMENT

 

Property and equipment, net, consists of the following:

   September 30, 2022   December 31, 2021 
Software  $25,890   $25,890 
Website development   91,622    91,622 
Software development   394,772    394,772 
Equipment   1,750    1,750 
Less: accumulated depreciation   (446,578)   (421,573)
Total property and equipment, net  $67,456   $92,461 

 

Depreciation expense for the period ended September 30, 2022 and 2021 was $25,005 and $7,103, respectively, and is included in general and administrative expenses.

 

14
 

 

6. INTANGIBLE ASSETS

 

Intangible assets, net, consists of the following:

 

           
  

September 30,

2022

  

December 31,

2021

 
Trademarks  $3,308   $- 
Less: accumulated amortization   -    - 
Total intangible assets, net  $3,308   $- 

 

Amortization expense for the period ended September 30, 2022 and 2021 was $0 and $0, respectively, and is included in general and administrative expenses.

 

7. NOTES & LOANS PAYABLE

 

The following table summarizes the components of our short-term borrowings:

   September 30,
2022
  

December 31,

2021

 
(a) Term loan  $150,875   $40,640 
(b) Revolving line of credit   7,000    7,000 
(b) Revolving line of credit   10,000    - 
Total  $167,875   $47,640 

 

(a) Term loans

In 2022, the Company entered into an unsecured short-term loan agreement with a third party for an aggregate principal balance of $25,000 at an interest rate of 3% per annum, with the interest adjusted to 10% in the case of a default. The term loan becomes due on May 30, 2022. The loan was paid in full on April 14, 2022.

 

In September of 2019, the Company entered into an unsecured term loan agreement with a third party for an aggregate principal balance of $50,000 at an interest rate of 5% per annum in relation to an Asset Purchase Agreement. The term loan became due on December 31, 2020, and is currently past due. The principal balance outstanding on the note as of December 31, 2021 was $40,640, which included $4,806 in interest and reductions of $9,360 due to sublet fees for office space. As of September 30, 2022 the principal balance outstanding on the note was $150,875, which included $120,000 in borrowings, $4,500 in principal and interest reductions, and $5,325 in reductions due to sublet fees for office space.

 

(b) Lines of Credit

 

The Company obtained a revolving line of credit agreement with an accredited investor of $500,000 during 2018. There were three borrowings against the line as of December 31, 2018 for aggregate borrowings of $65,000 and two borrowing in 2019 for $65,000 for a total of $130,000. During the period ended December 31, 2020, the Company repaid $76,000 in principal and all of its accrued interest of $4,204, resulting in a balance due of $22,000 as of December 31, 2020. During the period ended December 31, 2021, the Company repaid $10,000 in principal and all of its interest of $560, as incurred, resulting in a balance due of $7,000 as of September 30, 2022.

 

The line bears interest of 8.5%. The line is based upon GTX providing the investor with purchase orders and use of proceeds, including production of goods schedules and loan repayment timelines. These loans/drawdowns are specifically for product, inventory and/or purchase order financing. Upon completion of the terms of the Line of Credit, GTX Corp. will issue to the investor 7,500,000 shares of GTX common stock or $75,000 of GTX common stock, whichever is greater.

 

The Company also has an unsecured line of credit, guaranteed by its CEO, with its business bank, Union Bank, whereby funds can be borrowed at a revolving adjustable rate of 2 points over prime, currently 5.25%, with a max borrowing amount of $100,000. The balance at December 31, 2021 and September 30, 2022 was $0 and $10,000, with $59,180 having been borrowed and $59,180 paid back in the September 30, 2022 period.

 

15
 

 

8. CONVERTIBLE PROMISSORY NOTES – PAST DUE

 

As of September 30, 2022 and December 31, 2021, the Company had a total of $848,000 and $758,000, respectively, of outstanding convertible notes payable, which consisted of the following:

  

June 30,

2022

   December 31, 2021 
Convertible Notes – with fixed conversion  $843,000   $758,000 
Less: Debt discount   -    - 
Total convertible notes, net of debt discount  $843,000   $758,000 

 

  a) Included in Convertible Notes - with fixed conversion terms, are loans provided to the Company from various investors These notes carry simple interest rates ranging from 0% to 12% per annum and with terms ranging from 1 to 2 years. In lieu of the repayment of the principal and accrued interest, the outstanding amounts are convertible, at the option of the note holder, generally at any time on or prior to maturity and automatically under certain conditions, into the Company’s common shares at $0.015 to $0.30 per share. These notes became due in 2017 and prior, and are currently past due.

 

   

At December 31, 2020, balance of the convertible notes was $713,750. During the twelve months ended December 21, 2021, we issued 1,616,667 shares of common stock to convert $24,250 of principal of these outstanding convertible notes. The Company also paid down $8,750 of the principal balance of the convertible notes and the Company’s executives transferred $70,000 of their outstanding employee notes for cash to third parties, which lowered the related party notes and increased the convertible promissory notes by $70,000.

 

During the nine months ended September 30, 2022, an additional $100,000 of the Company’s executive notes were transferred to third parties for cash. The transferred notes had no change in terms thus no resulting gain or loss on the extinguishment and transfer. As per the original terms the notes bear a 10% annual interest rate, gives the holder the right, but not the obligation to convert up to 50% of the amount advanced and accrued interest into shares, warrants or options of common or preferred stock of the Company at fixed rate of $0.01 per share. As of September 30, 2022 the Company had paid off a $10,000 note with $4,639 of accrued interest for cash, and converted $5,000 of a note with $460 in accrued interest into 546,000 shares of common stock.

 

As of December 31, 2021, and September 30, 2022 $678,000 of these convertible notes are currently past due, with no associated penalties.

 

9. CARE Loans

   September 30, 2022   December 31, 2021 
a) PPP loan – short term  $-   $67,870 
b) EIDL loan – short term   6,625    7,083 
b) EIDL loan – long term   143,375    142,917 
Total CARE loans  $150,000   $217,870 

 

(a) Paycheck Protection Program Loan

 

On April 30, 2020, the Company executed a note (the “PPP Note”) for the benefit of MUFG Union Bank, NA (the “Lender”) in the aggregate amount of $67,870 under the Paycheck Protection Program (“PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The PPP is administered by the U.S. Small Business Administration (the “SBA”). The interest rate of the loan is 1.00% per annum and accrues on the unpaid principal balance computed on the basis of the actual number of days elapsed in a year of 360 days. Commencing seven months after the effective date of the PPP Note, GTX is required to pay the Lender equal monthly payments of principal and interest as required to fully amortize any unforgiven principal balance of the loan by the two-year anniversary of the effective date of the PPP Note (the “Maturity Date”). The Maturity Date can be extended to five years if mutually agreed upon by both the Lender and GTX. The PPP Note contains customary events of default relating to, among other things, payment defaults, making materially false or misleading representations to the SBA or the Lender, or breaching the terms of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding under the PPP Note, collection of all amounts owing from GTX, or filing suit and obtaining judgment against GTX. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. Recent modifications to the PPP by the U.S. Treasury and Congress have extended the time period for loan forgiveness beyond the original eight-week period, making it possible for GTX to apply for forgiveness of its PPP loan. No assurance can be given that GTX will be successful in obtaining forgiveness of the loan in whole or in part, as such the Company has moved the PPP Loan into short-term liabilities, until further instructions are received. The Company was in compliance with the terms of the PPP loan as of December 31, 2021, and has accrued interest on the loan of $1,160 as of December 31, 2021.

 

16
 

 

During the period ended September 30, 2022, the Company received notification that the loan was forgiven, and as such, $68,870 of principal has been recognized on the income statement under other income, as of September 30, 2022.

 

(b) Economic Injury Disaster Loan

 

On June 10, 2020, the Company executed a secured loan with the U.S. Small Business Administration (SBA) under the Economic Injury Disaster Loan program in the amount of $150,000. The loan is secured by all tangible and intangible assets of the Company and payable over 30 years at an interest rate of 3.75% per annum. Installment payments, including principal and interest, were supposed to start on June 10, 2021, but as of December 31, 2021 there has been no formal indication on whether this loan will be forgiven and no specific instructions have been received to-date from the SBA on how to proceed. As part of the loan, the Company also received an advance of $10,000 from the SBA. While the SBA refers to this program as an advance, it was written into law as a grant. This means that the amount given through this program does not need to be repaid and has been recognized as Other Income.

 

As of September 30, 2022, the Company calculated that 16 months of the 360 periods on the 30-year loans should be considered short-term (months since installment plan was supposed to begin), and as such $6,625 is considered short-term liabilities, has accrued interest on the loan of $13,750 as of September 30, 2022, or until the Company has received more definitive correspondence related to any potential forgiveness.

 

10. RELATED PARTY TRANSACTIONS

 

Convertible Notes Due to Related Parties

 

During the period ended December 31, 2021, the Company relieved the outstanding payables due to related parties by $200,000 and converted those amounts into additional notes with an aggregate amount of $200,000. As the conversion price embedded in the note agreements was below the trading price of the common stock on the dates of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $38,000 related to the intrinsic value of beneficial conversion feature. Additionally, the Company’s executives transferred $70,000 of their outstanding employee notes for cash to third parties, which lowered the related party notes and increased the convertible note balance by $70,000. The transferred notes had no change in terms, thus resulting in no gain or loss on the extinguishment related to the transfer of debt, making the outstanding balance on the related party notes on December 31, 2021 as $1,014,546, net of debt discounts.

 

During 2020, management elected to reduce the 10% annual interest rate to 3% because of the affects COVID-19 had on the U.S. economy. As such, on December 31, 2020 interest of $249,102 is deferred on the above notes and included in accrued expenses to related parties. The other 7% was considered imputed interest and is included as a separate line item on the equity statement accordingly.

 

On July 1, 2021, the annual interest on the notes was re-established to 10%, and as such, on December 31, 2021 the interest of $306,852, and on September 30, 2022 the interest on the notes was $382,889.

 

During the period ended September 30, 2022, the Company relieved the outstanding payables due to related parties by $367,901 and converted those amounts into additional notes with an aggregate amount of $367,901 with the same terms as those described above. The Company recognized a debt discount at the date of issuance in the aggregate amount of $168,951 related to the intrinsic value of beneficial conversion feature. Additionally, the Company’s executives transferred $100,000 of their outstanding employee notes for cash to third parties, which lowered the related party notes and increased the convertible note balance by $100,000. The transferred notes had no change in terms, thus resulting in no gain or loss on the extinguishment related to the transfer of debt.

 

On September 20, 2022, $108,602 of employee notes were converted into 10,860,200 of common stock.

 

17
 

 

As of September 30, 2022, the outstanding balance on the convertible promissory notes was $1,104,585, net of debt discounts.

 

Accrued wages and costs - In order to preserve cash for other working capital needs, various officers, members of management, employees and directors agreed to defer portions of their wages and sometimes various out-of-pocket expenses since 2011. As of September 30, 2022, and December 31, 2021, the Company owed $127,419 and $391,743, respectively, for such deferred wages and other expenses owed for other services which are included in the accrued expenses – related parties on the accompanying balance sheet.

 

11. DERIVATIVE LIABILITIES

 

Under authoritative guidance used by the FASB on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The Company has issued certain convertible notes which conversion prices are based on a future market price. However, since the number of shares to be issued is not explicitly limited, the Company is unable to conclude that enough authorized and unissued shares are available to share settle the conversion option. As a result, the conversion option is classified as a liability and bifurcated from the debt host and accounted for as a derivative liability in accordance with ASC 815 and will be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

 

At September 30, 2022 and December 31, 2021, the balance of the derivative liabilities was $0. It was determined at December 31, 2020 that the Preferred A shareholders having the majority vote, can agree to increase the number of authorized shares, if needed, to settle any convertible debt, and thus the liability is $0.

 

12. EQUITY

 

The Company has 10,000,000 shares of preferred stock authorized, giving the Board of Directors of this corporation the authorization to (A) determine the number of series into which shares of Preferred Stock may be divided, (B) to determine the designations, powers, preferences, voting and other rights, and the qualifications, limitations and restrictions granted to or imposed upon the Preferred Stock or any series thereof or any holders thereof, (C) to determine and alter the designations, powers, preferences and rights, and the qualifications, limitations and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock or the holders thereof, (D) to fix the number of shares of that series, and (E) to increase or decrease, within the limits stated in any resolutions of the Board of Directors originally fixing the number of the shares constituting any series (but not below the number of such shares then outstanding), the number the shares of any such series subsequent to the issuance of shares of that series.

 

On September 20, 2022, the Company effected 1-for-65 reverse stock split of its preferred shares. All share amounts and per share amounts have been retroactively restated to reflect the split as if it had occurred as of the earliest period presented.

 

From this pool the following preferred shares have been classified as:

 

Preferred Stock – Series A

 

During the year ended December 31, 2018, the Company authorized 15,385 of Series A preferred shares, the Series A Preferred Stock shall, collectively, at all times have super-majority voting power equal to two-thirds (2/3rds) of the votes available to be cast on any matter subject to a shareholder vote. The subject preferred stock lacks any dividend rights, does not have liquidation preference, and is not convertible into common stock. During the year ended December 31, 2018, the Company issued one million Series A preferred shares to certain officers and board members.

 

Effective January 31, 2020, Chris Walsh resigned from the Board of Directors and returned his 1,539 Preferred A shares to Treasury, resulting in 13,846 Preferred shares being outstanding currently.

 

At December 31, 2020 is was determined that the Preferred A shareholders having the majority vote, can agree to increase the number of authorized shares, if needed, to settle any convertible debt, and thus any derivative liabilities are not necessary to reserve for this.

 

18
 

 

Preferred Stock – Series B

 

During the year ended December 31, 2019, the Company authorized 10,000 shares of preferred stock to be designated available for Series B preferred shares that have a value of $1,000 each and are convertible into common shares at fixed price of $0.0025. Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Company’s Common Stock. No other dividends shall be paid on shares of Series B Preferred Stock, and they shall have no voting rights and have liquidation preference. During the year ended December 31, 2019, the Company issued 3 Series Preferred B shares and 30,000,000 warrants to an accredited investor for their financings for an aggregate value of $150,000.

 

During the period ended December 31, 2020, the Company issued 2 Series B preferred shares and 20,000,000 warrants to an accredited investor for their financings for an aggregate value of $50,000. The Series B preferred shares and warrants shall have a fixed conversion price equal to $0.0025 of common stock, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock. The warrants are exercisable at a price of $0.0025 per share through March 2025. The Company considered the accounting effects of the existence of the conversion feature of the Series B Preferred Stock, and the issuance of warrants at the date of issuance. In accordance with the current accounting standards, the Company determined that it should account for the fair value of the conversion feature and relative fair value of the issued warrants (up to the face amount of the Series B Preferred Stock) as a deemed dividend of $50,000 and a charge to paid in capital.

 

During the period ended December 31, 2021, the two accredited investors converted 2 Series B preferred shares into 28,000,000 common shares at the conversion price of $0.0025.

 

Preferred Stock – Series C

 

During the period ended December 31, 2020, the Company authorized 1,000 shares of preferred stock to be designated available for Series C preferred shares that have a stated value of $1,000 each and are convertible into common shares at fixed price of $0.015. Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Company’s Common Stock. No other dividends shall be paid on shares of Series C Preferred Stock, and they shall have no voting rights and have liquidation preference. During the year ended December 31, 2019, the Company had no Preferred C shares.

 

During the period ended December 31, 2020, the Company issued 3 Series C preferred shares and 10,000,000 warrants to two accredited investors for their financings for an aggregate value of $150,000.

 

During the period ended December 31, 2021, the Company issued 11 Series C preferred shares and 22,500,000 warrants to an accredited investor for their financings for an aggregate value of $675,000. The Series C preferred shares and warrants shall have a fixed conversion price equal to $0.004 per share of common stock, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock. The warrants are exercisable through May 2024. The Company considered the accounting effects of the existence of the conversion feature of the Series C Preferred Stock, and the issuance of warrants at the date of issuance. In accordance with the current accounting standards, the Company determined that it should account for the fair value of the conversion feature and relative fair value of the issued warrants (up to the face amount of the Series C Preferred Stock) as a deemed dividend of $675,000 and a charge to paid in capital.

 

During the period ended December 31, 2021, the two accredited investors converted 3 Series C preferred shares into 10,000,000 common shares at the conversion price of $0.015.

 

Common Stock

 

On September 20, 2022, the Company effected 1-for-65 reverse stock split of its common shares. All share amounts and per share amounts have been retroactively restated to reflect the split as if it had occurred as of the earliest period presented.

 

During the period ending September 30, 2022, the Company issued 459,692 shares of its common stock to various firms for services rendered, with a fair value of $129,286 based on the quoted market price of the shares at time of issuance.

 

19
 

 

During the period ended September 30, 2022, the Company issued 153,847 shares of common stock with a fair value of $25,000 at the date grant for the cash conversion of 10,000,000 warrants.

 

On October 15, 2021, the Company initiated a financing for gross proceeds of up to $2,000,250 through the issuance of 66,675,000 units at $.03 per unit, utilizing a Regulation A Offering Memorandum under the US Securities Act of 1933. The financing became effective on October 27, 2021. Each unit consists of one share of the Company’s common stock for a period beginning one year after the offering statement was qualified by the Securities and Exchange Commission. For the period ended September 30, 2022, gross proceeds of $180,000 were received and 92,309 common shares have been issued related to this offering. The Company spent $50,000 in total for legal and accounting fees to file and make the Regulation A effective.

 

Common Stock Warrants

 

Since inception, the Company has issued numerous warrants to purchase shares of the Company’s common stock to shareholders, consultants and employees as compensation for services rendered.

 

A summary of the Company’s warrant activity and related information is provided below (the exercise price and the number of shares of common stock issuable upon the exercise of outstanding warrants have been adjusted to reflect a 1-for-65 reverse stock split):

   Exercise
Price $
   Number of Warrants 
Outstanding and exercisable at December 31, 2021   0.162.60    757,692 
Warrants exercised   0.16    (153,846)
Warrants granted   -    - 
Warrants expired   -    - 
Outstanding and exercisable at September 30, 2022   0.162.60    603,846 

 

 

Stock Warrants as of September 30, 2022 
Exercise   Warrants   Remaining   Warrants 
Price   Outstanding   Life (Years)   Exercisable 
$0.16    100,000    2.38    100,000 
$0.98    157,692    1.09    157,692 
$2.60    346,154    1.51    346,154 

 

During the period ended September 30, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $25,000 at the date grant for the cash conversion of 10,000,000 warrants with a strike price of $0.0025 or (153,846 warrants at $0.016 accounting for the reverse stock split).

 

The outstanding and exercisable warrants at September 30, 2022 had an intrinsic value of approximately $223,423.

 

Common Stock Options

 

Under the Company’s 2008 Equity Compensation Plan (the “2008 Plan”), we are authorized to grant stock options intended to qualify as Incentive Stock Options, “ISO”, under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified options, restricted and unrestricted stock awards and stock appreciation rights to purchase up to 7,000,000 shares of common stock to our employees, officers, directors and consultants, with the exception that ISOs may only be granted to employees of the Company and its subsidiaries, as defined in the 2008 Plan.

 

The 2008 Plan provides for the issuance of a maximum of 7,000,000 shares, of which, after adjusting for estimated pre-vesting forfeitures and expired options, approximately 2,235,000 were available for issuance as of September 30, 2022.

 

No options were granted during the period ending September 30, 2022.

 

20
 

 

13. COMMITMENTS & CONTINGENCIES

 

Bonuses

 

The Company has an employment agreement with its CEO which, among other provisions, provide for the payment of a bonus, as determined by the Board of Directors, in amounts ranging from 15% to 50% of the executive’s yearly compensation, to be paid in cash or stock at the Company’s sole discretion, if the Company has an increase in year over year revenues and the Executive performs his duties (i) within the time frame budgeted for such duties and (ii) at or below the cost budgeted for such duties. No such bonuses were declared or accrued during the periods ending September 30, 2022 or 2021.

 

Contingencies

 

From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. As of September 30, 2022, there was no pending or threatened litigation against the Company.

 

Covid-19

 

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

 

Due to COVID-19, we experienced some changes in our business, that have been both positive and negative. Specifically, the Company’s IP licensing business has been negatively impacted by the global financial slowdown and many courts, judges and law firms are not working at full capacity, which created delays in finalizing licensing agreements or litigation. We have also experienced a small percentage of subscriptions being either cancelled or requested to be put on pause, due to financial hardships. On the positive side we saw an increase in product sales specifically with medical supplies and equipment. Overall, our revenues have not been materially impacted as a whole, however there have been some shifts with certain revenue streams doing better post COVID and others doing worse.

 

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

 

14. SUBSEQUENT EVENTS

 

On October 28, 2022 we issued 34,000 shares to a consultant for services valued at $6,290.

 

21
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our revenues and financial performance; risks associated with product development and technological changes; the acceptance our products in the marketplace by existing and potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

 

Introduction

 

Unless otherwise noted, the terms “MetAlert”, the “Company”, “we”, “us”, and “our” refer to the ongoing business operations of MetAlert Inc. (formerly known as GTX Corp) and our wholly-owned subsidiaries, Global Trek Xploration, and LOCiMOBILE, Inc.

 

Organization and Presentation

 

During the periods covered by the accompanying financial statements, MetAlert, Inc. and its subsidiaries were engaged in business operations that design, manufacture and sell various interrelated and complementary products and services in the wearable technology and Personal Location Services marketplace. MetAlert owns 100% of the issued and outstanding capital stock of its two subsidiaries - Global Trek Xploration, Inc. and LOCiMOBILE, Inc.

 

Global Trek Xploration is a California corporation which engages in the business of design, development, manufacturing, and sales of health and safety wearable technology solutions. Utilizing Global Positioning Satellite (“GPS”), Cellular, Radio Frequency (“RF”), Near Field Communications (“NFC”), WiFi, and Bluetooth low energy (“BLE”) as core technologies for monitoring and tracking assets. GTX is vertically integrated and provides hardware, software, and connectivity, delivering a complete end to end location-based platform that enables subscribers to track in real time the whereabouts of people, pets, or high valued assets. Our proprietary GPS devices, which consist of a miniature quad-band General Packet Radio Service (“GPRS”) transceiver, custom antenna, circuitry, battery, and inductive charging pad can be customized and integrated into numerous form factors. The finished products are then placed or worn so that their location and movement can be monitored in real time over the Internet through our 24x7 tracking portal or on a web-enabled cellular telephone.

 

Many of our core products and services are supported by an intellectual property portfolio of patents, patents pending, registered trademarks, copyrights, URLs and a library of software source code, all of which is also managed by Global Trek.

 

LOCiMOBILE, Inc., is the Company’s digital platform which has been at the forefront of Smartphone application (“App”) development since 2008. With a suite of mobile applications that turn the iPhone, iPad, Android and other GPS enabled handsets into a tracking device which can be tracked from handset to handset or through our tracking portal or on any connected device with internet access. LOCiMOBILE has launched over 20 Apps across multi mobile device operating systems and continues to launch consumer and enterprise apps.

 

22
 

 

Operations

 

The Company designs, develops, manufactures, sells, and distributes health and safety products and services, and other related medical supplies and equipment, through a global business to business (“B2B”) network of resellers, affiliates, distributors, nonprofit organizations, local, state, and federal government agencies, police departments, manufacturers reps and retailers, and direct business to consumer (“B2C”). Offering a variety of electronic and non-electronic devices and equipment, a proprietary Internet of things (“IoT”) enterprise monitoring platform and a licensing subscription business model. The Company provides a complete end to end solution of hardware, middleware, apps, connectivity, licensing, and professional services, letting our customers know where or how someone, or something, is at the touch of a button, delivering safety, security, and peace of mind in real-time. Except for our military products and medical protective equipment, all of our consumer and enterprise tracking products funnel into the MetAlert’s IoT monitoring platform which supports end user customers in over 35 countries. The Company is also in the business of licensing intellectual property and monetizing its patent portfolio.

 

Overview

 

During the third quarter of 2022, we undertook evolutionary steps to transform and rebrand the company. We initiated multiple corporate actions, including a name change from GTX Corp to MetAlert Inc., ticker symbol change from GTXO to MLRT, CUSIP number change and we effectuated a reverse stock split. We started the process in June of 2022 and successfully finalized all of our corporate actions on October 19, 2022.

 

Senior management and the board of directors strongly believed these initiatives were in the long-term best interest of the company and its shareholders for several reasons. Our previous name no longer reflected and symbolized our mission and purpose and even though we are and have been fully reporting S.E.C. Company for over 14 years, being a penny stock on the OTC Pink Open Market was not providing us with all the benefits of being a public company. We did not have significant market liquidity because of the trading volatility often associated with low-priced stocks, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced (sub-penny) stocks or tend to discourage individual brokers from recommending low-priced stocks to their clients. The Board believes that the resulting price per share after the reverse stock split will help enable the Company to meet the initial listing requirements of a higher broker-dealer network or exchange listing and such an occurrence will attract more potential investors resulting in a more liquid public market. Optically, MetAlert trading with a much higher share on a more senior exchange or broker-dealer market, is more advantageous than GTX Corp trading on the OTC Pink Open Market hovering under 2 cents.

 

During these past 4 months we had several regulatory bodies such as the SEC, FINRA, the State of Nevada, lawyers and auditors review the company thoroughly and we believe having successfully completed all our initiatives well positions the Company to achieve its aspirations to list to NASDAQ.

 

The transformation and rebranding will help facilitate some of our next business initiatives, such as applying for Medicare reimbursement, looking into various complimentary acquisitions, the integration of other wearable medical devices into our SmartSole platform, building our network of partners and adding new distribution channels.

 

As part of the rebranding, the Company will be expanding its product line and will no longer merely sell tracking solutions, but rather more comprehensive remote patient monitoring solutions. Management believes this will enable us to grow both vertically and horizontally. Vertically because we will be offering more than just tracking locations, we will be including fall detection, biometrics, analytics, telehealth, and a host of other related medical services. We plan to also grow horizontally and expand our target audience beyond seniors with Alzheimer’s or dementia, or children with autism. We are now looking at a much broader range of individuals that may have cognitive decline and other ailments and need other remote patient monitoring services. The combination of these factors should help broaden our revenue base in the coming years, by adding those additional services to our monthly recurring service fees, which now range between $5.00 to $100 per month per device.

 

23
 

 

The above-mentioned endeavors required significant time and effort, that combined with a component recall from one of our suppliers, impacted our ability to generate meaningful revenues in the third quarter. The component recall made it such that we could not manufacture any new inventory of our GPS SmartSoles. As we had very little inventory left from the second quarter, we were only able to ship smaller than anticipated quantities of SmartSoles to our customers in Q3. However, we received the new component, and the factory is in the process of replacing the old component with the new.

 

This situation has created a significant backlog of orders, which we expect to fulfil over the coming months. We have raw component inventory to make several thousand units, which is still below what we need in total to fulfil backorders but as the supply chain issues improve, we expect to be able to order additional components with shorter lead times starting early next year.

 

As we discussed in our last Form 10-Q, our NFC/NFT business has been increasing and we saw a 342% increase over the second quarter and expect this business unit to continue to grow. It is a part of our business we are looking to expand as it is not so much reliant on supply chain issues and component sourcing. We believe by adding three or four more customers like endstate, and this could become a strong source of revenue for us.

 

On the strategic side, we have:

 

Added several new partners, including RoomMate and POD Group;
Started testing with new distributors in Europe;
Hired a new salesperson that will be solely working certain vertical markets and channels for both SmartSoles and the RoomMate products;
Began testing preproduction devices from our partnership with GBT and;
Hired several new marketing firms to help tell our story to the business and investment community at large about our transformation into MetAlert.

 

For the remainder of the year, we still have a lot of work ahead of us, as we, prepare to launch our new 3D infrared remote patient monitoring and fall detection system called RoomMate. We continue the integration development and testing of the GBT technology into our SmartSole plus, we look to bring on new NFC customers, restart our GPS SmartSole production and fill back orders, and apply for an up list to a more senior exchange.

 

Results of Operations

 

The following discussion should be read in conjunction with our interim consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report.

 

24
 

 

Three Months Ended September 30, 2022 (“Q3 2022”) Compared to the Three Months Ended September 30, 2021 (“Q3 2021”)

 

   Three Months Ended September 30, 
   2022   2021 
   $   % of Revenues   $   % of Revenues 
                 
Product sales   36,352    54%   112,974    75%
Service income   31,302    46%   38,580    25%
IP royalties   -    0%   -    0%
Total revenues   67,654    100%   151,554    100%
Cost of products sold   23,353    35%   58,001    38%
Cost of service revenue   3,016    4%   10,129    7%
Cost of licensing revenue   -    0%   -    0%
Cost of goods sold   26,349    39%   68,130    45%
Gross profit   41,305    61%   83,424    55%
                     
Operating expenses:                    
Wages and benefits   127,829    189%   138,137    91%
Professional fees   81,893    121%   65,902    43%
Sales and marketing expenses   3,494    5%   5,083    3%
General and administrative   68,269    101%   70,001    46%
Total operating expenses   281,485    416%   279,123    184%
                     
Gain/(loss) from operations   (240,180)   -355%   (195,699)   -129%
                     
Other (expense)/income, net   (62,283)   -92%   (16,432)   -11%
Net income/(loss)   (302,463)   -447%   (212,131)   -140%

 

Revenues

 

Revenues were $67,654 for the three months ended September 30, 2022 as compared to $151,554 for the three months ended September 30, 2021, representing a decrease of 55%, This decrease was primarily driven from transitioning out of direct-to-consumer PPE sales during Covid into our core B2B business.

 

During Q3 2022, the Company’s customer base and revenue streams were comprised of approximately 59% B2B (Wholesale Distributors and Enterprise Institutions), 41% B2C (consumers and government agencies who bought on the behalf of consumers, through our online ecommerce platform and through Amazon, Google and iTunes.

 

During Q3 2021, the Company’s customer base and revenue streams were comprised of approximately 40% B2B (Wholesale Distributors and Enterprise Institutions), 51% B2C (consumers and government agencies who bought on the behalf of consumers, through our online ecommerce platform and through Amazon, Google and iTunes), 0% IP (our monetization campaign from consulting, licensing and asserting our patents), 6% Military and Law Enforcement and 4% in donations to various groups.

 

Cost of goods sold

 

Cost of goods sold were $26,349 for the Q3 2022 compared to $68,130 for the Q3 2021, representing a decrease of 61%. This decrease was primarily due to the shift from COVID related PPE’s with less margins, to the higher margin 4G SmartSoles and the increase in recurring fees.

 

We expect our margins to increase in 2022 once we start ramping up our subscriptions and licensing and sell more of our proprietary products like our SmartSoles, where we have no or limited competition. Our overall gross margin was slightly lower in 2021, predominately because most of our revenues came from product sales which require competitive pricing, and that includes shipping charges. In order to be competitive with the major online retailers (many of them include free shipping) we had to reduce our shipping charges to be in line with competitors.

 

Wages and benefits

 

Wages and benefits decreased $10,308, or 7%, in Q2 2022 as compared to Q3 2021. This decrease was primarily the result of one of our executive sales staff taking on less duties as we transition back into our core GPS and SmartSole business.

 

Professional fees

 

Professional fees consist of costs attributable to consultants and contractors who primarily spend their time on legal, accounting, product development, business development, corporate advisory services and shareholder communications. Such costs increased $15,991 or 24% in Q3 2022 as compared to in Q2 2021. Even though some professional fees have decreased as more responsibilities were transferred from outside contractors and consultants to in-house personnel. Those fees related to investor relations, business development and the recent corporate actions have increased due to new products lines and the impending release of the company’s updated SmartSole products.

 

25
 

 

Sales and marketing expenses

 

Sales and marketing expenses decreased by 31% or $1,589 in Q3 2022 in comparison to Q3 2021. This decrease was primarily due to a large Company awareness campaign in 2021 compared to 2022.

 

General and administrative

 

General and administrative costs in Q3 2022 decreased by $1,732 or 2% in comparison to Q3 2021, mostly due to adjustments to prior period accruals.

 

Other income/(expense), net

 

Other expense, net increased 279% or $44,481 in Q3 2022 compared to Q3 2021. This increase was primarily as a result of the amortization of debt discounts and interest expense.

 

Net income/(loss)

 

Net loss increased by 43% or $90,334 from Q3 2022 to Q3 2021 primarily as a result of the increase in the amortization of debt discounts and interest expense.

 

Nine Months Ended September 30, 2022 (“Q1–Q3 2022”) Compared to the Nine Months Ended September 30, 2021 (“Q1–Q3 2021”)

 

   Nine Months Ended September 30, 
   2022   2021 
   $   % of Revenues   $   % of Revenues 
                 
Product sales   200,277    67%   397,963    73%
Service income   100,293    33%   143,715    27%
IP royalties   -    0%   -    0%
Total revenues   300,570    100%   541,678    100%
Cost of products sold   147,627    49%   200,055    37%
Cost of service revenue   15,906    5%   63,556    12%
Cost of licensing revenue   -    0%   -    0%
Cost of goods sold   163,173    54%   263,611    49%
Gross profit   137,397    46%   278,067    51%
                     
Operating expenses:                    
Wages and benefits   382,916    127%   385,099    71%
Professional fees   257,232    86%   263,862    49%
Sales and marketing expenses   19,092    6%   74,821    14%
General and administrative   156,670    52%   159,702    29%
Total operating expenses   815,910    271%   883,484    163%
                     
Gain/(loss) from operations   (678,514)   -226%   (605,417)   -112%
                     
Other (expense)/income, net   (44,558)   -15%   (152,629)   -28%
Net income/(loss)   (723,072)   -241%   (758,046)   -140%

 

26
 

 

Revenues

 

Revenues as a whole in Q1-Q3 2022 decreased by 45% or $241,108 in comparison to Q1-Q3 2021, a result of the reduction in demand for PPP’s and the inability to ship any SmartSoles during the 1st quarter due to supply chain delays. We continue to fulfill pre-sale orders daily and expect SmartSole production to catch up with orders over the next few quarters. Additionally, we are seeing an uptick in PPE demand and increased sales as a result of the new COVID spike.

 

Cost of goods sold

 

Cost of goods sold decreased by 38% or $100,439 during Q1-Q3 2022 in comparison to Q1-Q3 2021 primarily due to the shift from purchases of low margin health and safety inventories to the higher margin SmartSoles.

 

Wages and benefits

 

Wages and benefits during Q1-Q3 2022 decreased by 1% or $2,183 in comparison to Q1-Q3 2021, primarily due to employee benefits and conferences.

 

Professional fees

 

Professional fees consist of costs attributable to consultants and contractors who primarily spend their time on legal, accounting, product development, business development, corporate advisory services and investor relations and the recent corporate actions. Such costs decreased $6,630 or 3% during Q1-Q3 2022 as compared to Q1-Q3 2021, primarily due to the Company’s decreased need for outside consultants.

 

Sales and marketing expenses

 

Sales and marketing expenses decreased by 74% or $55,729 during Q1-Q3 2022 in comparison to Q1-Q3 2021. Primarily due to costs related to the ramp up of increased health and safety products and the associated advertising in 2021.

 

General and administrative

 

General and administrative costs during Q1-Q3 2022 decreased by $3,031 or 2% in comparison to Q1-Q3 2021, thus remaining constant with reductions in insurance fees and corporate expenses being offset with increased product development and general occupancy costs.

 

Other income/(expense), net

 

Other expense, net decreased 71% or $108,070 from Q1-Q3 2022 to Q1-Q3 2021 primarily as a result of a $67,870 from the forgiveness of a CARE loan, the decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid. These gains offset the increase in interest expense and financing cots related to debt and the Reg A.

 

Net income/(loss)

 

Net loss decreased by 5% or $34,974 from Q1-Q3 2022 to Q1-Q3 2021 primarily as a result of $67,870 from the forgiveness of a CARE loan, the decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid, all while operating expenses remaining fairly stable during the transition from health and safety products back to our core GPS and SmartSole business.

 

Liquidity and Capital Resources

 

As of September 30, 2022, we had $23,998 of cash and cash equivalents, and a working capital deficit of $3,021,385, compared to $138,342 of cash and cash equivalents and a working capital deficit of $2,829,165 as of December 31, 2021.

 

27
 

 

During the nine months ended September 30, 2022, our net loss was $723,072 compared to a net loss of $758,046 for the nine months ended September 30, 2021. Net cash used in operating activities in the nine months ended September 30, 2022 and in the nine months ended September 30, 2021 was $426,835 and $378,026, respectively.

 

Net cash used in investing activities during the nine months ended September 30, 2022 was $3,308 for the purchase of intangible assets, as compared to net cash used in investing activities during the nine months ended September 30, 2021 which was $63,242 which consisted of proceeds totaling $1,258 received from the sale of marketable securities and $64,500 in developments cost assets.

 

Net cash provided by financing activities during the nine months ended September 30, 2022 was $315,799 and consisted of $180,000 received from the purchase of 6,000,000 shares of common stock (92,309 post reverse) at $0.03 per share, $25,000 received for the conversion of warrants, $145,000 from the issuance of debt and $69,180 from draws upon our line of credit. This was offset by payments on debt of $44,201 and $59,180 on the line of credit. Net cash used by financing activities during the nine months ended September 30, 2021 was $657,877 and consisted of $17,123 in payments to our lines of credit and a term loan, and $675,000 received from financings.

 

Because revenues from our operations have, to date, been insufficient to fund our working capital needs, we currently rely on the cash we receive from our financing activities to fund our growth, capital expenditures and to support our working capital requirements. The sale of our products and services is expected to enhance our liquidity in 2022, although the amount of revenues we receive in 2022 still cannot be estimated.

 

Until such time as our products and services can support our working capital requirement, we expect to continue to generate revenues from our other licenses, subscriptions, international distributors, hardware sales, professional services and new customers in the pipeline. However, the amount of such revenues is unknown and is not expected to be sufficient to fund our working capital needs. For our internal budgeting purposes, we have assumed that such revenues will not be sufficient to fund all of our planned operating and other expenditures during 2022. In addition, our actual cash expenditures may exceed our planned expenditures, particularly if we invest in the development of improved versions of our existing products and technologies, and if we increase our marketing expenses. Accordingly, we anticipate that we will have to continue to raise additional capital in order to fund our operations in 2022 No assurance can be given that we will be able to obtain the additional funding we need to continue our operations.

 

In order to continue funding our growth, IP and working capital needs and new product development costs, during the second quarter of 2022 we continued to draw down on our credit line to fund purchase orders. However, no assurance can be given that the investor will provide the funding, if and when requested by us.

 

Going Concern

 

The consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has stockholders’ deficit of $3,093,996 and negative working capital of $3,021,385 as of September 30, 2022 and used cash in operations of $426,835 during the current period then ended. A significant part of our negative working capital position at September 30, 2022 consisted of $2,122,085, net of debt discounts, of amounts due to various accredited investors of the Company for convertible promissory notes, loans and letters of credit. The Company anticipates further losses in the development of its business. Please see the section entitled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2021 for more information regarding risks associated with our business.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Inflation

 

We do not believe our business and operations have been materially affected by inflation.

 

28
 

 

Critical Accounting Policies and Estimates

 

There are no material changes to the critical accounting policies and estimates described in the section entitled “Critical Accounting Policies and Estimates” under Item 7 in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a “smaller reporting company”, we are not required to provide the information under this Item 3.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, including our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

 

Based on the evaluation as of September 30, 2022, for the reasons set forth below, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

None.

 

ITEM 1A. RISK FACTORS.

 

These are not all of the risks associated with the Company and must be used in conjunction with those disclosed in the most recent December 31, 2021 10K filing.

 

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

 

29
 

 

Due to COVID-19, we have experienced some changes in our business, that have been both positive and negative. Specifically, the Company’s IP licensing business has been negatively impacted by the global financial slowdown and many courts, judges and law firms are not working at full capacity, which is creating delays in finalizing licensing agreements or litigation. We have also experienced a small percentage of subscriptions being either cancelled or requested to be put on pause, due to financial hardships. On the positive side we saw an increase in product sales specifically with medical supplies and equipment. Overall, our revenues have not been materially impacted as a whole, however there have been some shifts with certain revenue streams doing better post COVID and others doing worse.

 

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

 

ITEM 2.(a). UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On January 14, 2022, we issued 4,000,000 in common stock, valued at $39,600 to a firm as part of their agreement.

 

On January 21, 2022, an investor converted 10,000,000 of warrants into 10,000,000 shares of common stock at a strike of $0.0025 for $25,000 in cash.

 

On April 1, 2022, we issued 1,200,000 in common stock, valued at $11,400 to a firm as part of their agreement.

 

On April 6, 2022, an investor invested $150,000 in the Company’s Reg A and received 5,000,000 of shares of common stock at a price of $0.03.

 

On April 12, 2021, we issued 1,904,762 in restricted common stock to a firm as part of their agreement with a value of $18,476 on the date of the agreement.

 

On April 1, 2022, we issued 1,200,000 in common stock, valued at $11,400 to a firm as part of their agreement.

 

On May 12, 2022, we issued 500,000 in common stock, valued at $3,450 to a firm as part of their agreement.

 

O July 20, 2022, an investor invested $30,000 in the Company’s Reg A and received 1,000,000 of shares of common stock at a price of $0.03.

 

On September 20, 2022, the Company’s 65-1 reverse of its common shares was approved by FINRA.

 

On September 20, 2022, the Company issued 11,406,200 shares for the conversion for various notes to related parties at a fixed price of $0.01.

 

On September 26, 2022, the Company issued 242,693 shares to various consultants for services valued at $37,860.

 

On September 28, 2022, the Company issued 100,00 shares to a consultant for services valued at $18,500.

 

The issuance of the above shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

30
 

 

ITEM 5. OTHER INFORMATION.

 

None.

 

ITEM 6. EXHIBITS.

 

(a) Exhibits

 

3.1   Restated Certificate of Incorporation as filed on September 14, 2022 with the State of Nevada
     
3.2  

Certificate of Amendment of GTX Corp, filed September 12, 2022(1)

     
3.3  

Certificate of Change of Metalert, Inc., filed September 12, 2022(1)

     
3.4   Amended and Restated Bylaws of Metalert, Inc., as of September 20, 2022(1)
     
31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
32.1   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act
     
32.2   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema
     
101.CAL   Inline XBRL Taxonomy Extension Calculation
     
101.DEF   Inline XBRL Taxonomy Extension Definition
     
101.LAB   Inline XBRL Taxonomy Extension Label
     
101.PRE   Inline XBRL Taxonomy Extension Presentation
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

  (1) Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 22, 2022.

 

31
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Metalert, Inc.
     
Date: November 15, 2022 By: /s/ ALEX MCKEAN
    Alex McKean,
    Chief Financial Officer (Principal Financial Officer)

 

Date: November 15, 2022 By: /s/ PATRICK BERTAGNA
    Patrick Bertagna,
    Chief Executive Officer

 

32

 

 

Exhibit 3.1

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

EXHIBIT 31.1

 

CERTIFICATIONS PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

 

I, Patrick E. Bertagna, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Metalert, Inc. for the period ended September 30, 2022;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 15, 2022

 

  /s/ PATRICK E. BERTAGNA  
Name: Patrick E. Bertagna  
Its: Chief Executive Officer (Principal Executive Officer)  

 

 

 

 

EXHIBIT 31.2

 

CERTIFICATIONS PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

 

I, Alex McKean, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Metalert, Inc. for the period September 30, 2022;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 15, 2022

 

  /s/ ALEX MCKEAN  
Name: Alex McKean  
Its: Chief Financial Officer (Principal Financial Officer)  

 

 

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Metalert, Inc. (the “Company”) on Form 10-Q, for the period ended September 30, 2022 as filed with the Securities and Exchange Commission, I, Patrick E. Bertagna, President, Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 15, 2022

 

  /s/ PATRICK E. BERTAGNA  
Name: Patrick E. Bertagna  
Its: Chief Executive Officer (Principal Executive Officer)  

 

 

 

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Metalert, Inc. (the “Company”) on Form 10-Q, for the period ended September 30, 2022 as filed with the Securities and Exchange Commission, I, Alex McKean, Interim Chief Financial Officer, Treasurer and Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 15, 2022

 

  /s/ ALEX MCKEAN  
Name: Alex McKean  
Its: Chief Financial Officer (Principal Financial Officer)